| 项目编号 |
PRJCA045195 |
| 项目标题 |
Phase II trial of tislelizumab and hypofractionated radiotherapy, plus nab-paclitaxel/gemcitabine (THAG) as preoperative therapy for BPRC/LAPC |
| 涉及领域 |
Medical |
| 数据类型 |
Biomarkers
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This phase II trial enrolled 56 BRPC/LAPC patients. Participants received tislelizumab plus AG (nab-paclitaxel/gemcitabine) in 21-day cycles. Non-progressing patients received concurrent radiotherapy during the third chemotherapy cycle. After four treatment cycles, a multidisciplinary team (MDT) assessed eligibility for radical surgery. Dynamic multi-omics molecular profiling was performed. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-08-25 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| Jiangsu Commission of Health
|
|
ZDXK202233
|
the Provincial Key Medical Disciplines During the 14th Five-Year Plan Period
|
| Drum Tower Hospital
|
|
2023-LCYJ-PY-29
|
Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
|
| Ministry of Science and Technology of the People's Republic of China (MOST)
|
|
2020YFA0713804
|
National Key Research and Development Program of China
|
|
|
| 提交者 |
Juan
Du (juandunjglyy@163.com)
|
| 提交单位 |
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School |
| 提交日期 |
2025-08-25 |
